Cytapheresis--the next 25 years: stem cell therapy.
Hemopoietic stem cell transplantation therapy has firmly established a role in the management of a range of malignant and nonmalignant disorders. Allogeneic bone marrow transplantation has been used as an adjunct in the treatment of acute leukemia with impressive results that have translated into long-term survival and cure. This experience has now extended to the management of other hematological malignancies and some solid tumors. With the ability to source hemopoietic stem cells from the peripheral blood by in vivo cytapheresis, there has been a rapid growth in the use of this form of therapy. The risks and benefits must be clearly appreciated and appropriate resources available with associated monitoring and quality assurance. There are few areas of medicine for which such close cooperation is necessary between medical, nursing, scientific, and allied health professionals to achieve successful outcomes. This paper addresses the logistical aspects of the provision of hemopoietic stem cell therapy in a routine clinical setting.